VRX
$15.31
Valeant Pharmaceuticals Intl
($.14)
(.91%)

Earnings History

Earnings
Revenue
Reaction
Drift
In-line Guidance
FY 2012
2/27/2012
8:00:00 AM
$3.95 to $4.20
5.5%
10.9%
Guidance:
Consensus:
Valeant Pharmaceuticals Guides In-line

Valeant Pharmaceuticals International said it expects 2012 earnings of $3.95 to $4.20 per share. The current consensus earnings estimate is $4.08 per share for the year ending December 31, 2012.
EPS & Revenue Above Estimates
FY 2012
5/3/2012
8:00:00 AM
$4.45 to $4.70
$3.40 bil to $3.60 bil
$4.06
$3.35 bil
-9.2%
-7.2%
Guidance:
Consensus:
Valeant Pharmaceuticals Raises Guidance

Valeant Pharmaceuticals International said it now expects 2012 earnings of $4.45 to $4.70 per share on revenue of $3.40 billion to $3.60 billion. The company's previous guidance was earnings of $3.95 to $4.20 per share and the current consensus earnings estimate is $4.06 per share on revenue of $3.35 billion for the year ending December 31, 2012.
EPS Above Estimates
FY 2012
8/2/2012
7:00:00 AM
$4.55 to $4.70
$3.40 bil to $3.60 bil
$4.42
0.1%
8.3%
Guidance:
Consensus:
Valeant Pharmaceuticals Raises Earnings Guidance

Valeant Pharmaceuticals International said it now expects 2012 earnings of $4.55 to $4.70 per share and continues to expect revenue of $3.40 billion to $3.60 billion. The company's previous guidance was earnings of $4.45 to $4.70 per share and the current consensus earnings estimate is $4.42 per share for the year ending December 31, 2012.
In-line Guidance
Q 12/2012
11/2/2012
6:00:00 AM
$1.30 to $1.35
$1.31
-0.7%
-6.6%
Guidance:
Consensus:
Valeant Pharmaceuticals Guides In-line

Valeant Pharmaceuticals International said it expects fourth quarter earnings of $1.30 to $1.35 per share. The current consensus earnings estimate is $1.31 per share for the quarter ending December 31, 2012.
Raises Guidance In-line with Estimates
FY 2013
5/2/2013
6:00:00 AM
$5.55 to $5.85
$5.59
-2.1%
-2.2%
Guidance:
Consensus:
Valeant Pharmaceuticals Raises Guidance, but Remains In-line with Estimates

Valeant Pharmaceuticals International said it expects 2013 earnings of $5.55 to $5.85 per share. The company's previous guidance was earnings of $5.45 to $5.75 per share and the current consensus earnings estimate is $5.59 per share for the year ending December 31, 2013.
Q3 Below/FY Above
FY 2013
8/7/2013
6:00:00 AM
$6.00 to $6.20
earnings of $5.82
1.9%
7.3%
Guidance:
Consensus:
Valeant Pharmaceuticals Raises 2013 Guidance

Valeant Pharmaceuticals International said it expects third quarter earnings of $1.33 to $1.43 per share and now expects 2013 earnings of $6.00 to $6.20 per share. The company's previous guidance was 2013 earnings of $5.55 to $5.85 per share. The current consensus earnings estimate is $1.44 per share for the quarter ending September 30, 2013 and earnings of $5.82 per share for the year ending December 31, 2013.
Narrows Guidance Above Estimates
FY 2013
10/31/2013
6:00:00 AM
$6.11 to $6.16
$5.70 bil to $5.90 bil
$6.06
-3.1%
-3.2%
Guidance:
Consensus:
Valeant Pharmaceuticals Narrows Guidance Above Estimates

Valeant Pharmaceuticals International said it expects 2013 earnings of $6.11 to $6.16 per share on revenue of $5.70 billion to $5.90 billion. The company's previous guidance was earnings of $6.00 to $6.20 per share and the current consensus earnings estimate is $6.06 per share for the year ending December 31, 2013.
Reaffirms
FY 2014
2/27/2014
6:00:00 AM
$8.25 to $8.75
1.1%
-8.4%
Guidance:
Consensus:
Valeant Pharmaceuticals Reaffirms

Valeant Pharmaceuticals International said it continues to expect 2014 earnings of $8.25 to $8.75 per share. The current consensus earnings estimate is $8.71 per share for the year ending December 31, 2014.
Raises Guidance In-line with Estimates
FY 2014
4/22/2014
7:30:00 AM
$8.55 to $8.80
7.5%
0.6%
Guidance:
Consensus:
Valeant Pharmaceuticals Raises Guidance, but Remains In-line with Estimates

Valeant Pharmaceuticals International said it expects to meet or beat the consensus earnings estimate of $1.74 per share for the first quarter ended March 31, 2014 and now expects 2014 earnings of $8.55 to $8.80 per share. The company's previous guidance was earnings of $8.25 to $8.75 per share and the current consensus earnings estimate is $8.67 per share for the year ending December 31, 2014.
Revenue Above Estimates
Q 09/2014
9/24/2014
9:05:00 AM
6.9%
10.0%
Guidance:
Consensus:
Valeant Pharmaceuticals to Beat Estimates

Valeant Pharmaceuticals International said it expects revenue to be above the current consensus estimate of $297.1 million for the fiscal third quarter ending September 30, 2014.
EPS Above Estimates
Q 12/2014
10/20/2014
7:00:00 AM
$2.45 to $2.55
$2.38
3.8%
7.8%
Guidance:
Consensus:
Valeant Pharmaceuticals Guides Above Estimates

Valeant Pharmaceuticals International said it expects fourth quarter non-GAAP earnings of $2.45 to $2.55 per share. The current consensus earnings estimate is $2.38 per share for the quarter ending December 31, 2014. The company also said it now expects 2015 earnings of approximately $10.00 per share. The company's previous guidance was earnings of $9.65 per share and the current consensus earnings estimate is $9.58 per share for the year ending December 31, 2015.
EPS Above Estimates
Q 03/2015
2/23/2015
4:27:19 AM
at least $2.30
$2.27
14.7%
7.0%
Guidance:
Consensus:
Valeant Pharmaceuticals Guides Above Estimates

Valeant Pharmaceuticals International said it expects first quarter non-GAAP earnings of at least $2.30 per share. The current consensus earnings estimate is $2.27 per share for the quarter ending March 31, 2015.
EPS Above Estimates
FY 2015
4/29/2015
6:00:00 AM
$10.90 to $11.20
$10.4 bil to $10.6 bil
$10.48
4.2%
5.8%
Guidance:
Consensus:
Valeant Pharmaceuticals Raises Guidance

Valeant Pharmaceuticals International, Inc. said it expects second quarter earnings of $2.40 to $2.50 per share on revenue of $2.45 billion to $2.55 billion. The current consensus earnings estimate is $2.47 per share for the quarter ending June 30, 2015. The company said it expects 2015 earnings of $10.90 to $11.20 per share on revenue of $10.4 billion to $10.6 billion. The company's previous guidance was earnings of $10.10 to $10.40 per share on revenue of $9.2 billion to $9.3 billion and the current consensus earnings estimate is $10.48 per share for the year ending December 31, 2015.
EPS & Revenue Above Estimates
FY 2015
7/23/2015
6:00:00 AM
$11.50 to $11.80
$10.70 bil to $11.10 bil
$11.05
6.2%
1.3%
Guidance:
Consensus:
Valeant Pharmaceuticals Raises Guidance

Valeant Pharmaceuticals International, Inc. said it expects third quarter earnings of $2.60 to $2.70 per share on revenue of $2.60 billion to $2.80 billion and now expects 2015 earnings of $11.50 to $11.80 per share on revenue of $10.70 billion to $11.10 billion. The company's previous guidance was 2015 earnings of $10.90 to $11.20 per share on revenue of $10.40 billion to $10.60 billion. The current consensus earnings estimate is $2.84 per share on revenue of $2.73 billion for the quarter ending September 30, 2015 and $11.05 per share on revenue of $10.49 billion for the year ending December 31, 2015.
Updates Guidance
Q 12/2015
10/19/2015
6:00:00 AM
$4.00 to $4.20
$4.00
$3.31 bill
-7.7%
-35.2%
Guidance:
Consensus:
Valeant Updates Guidance

Valeant Pharmaceuticals International, Inc. said it expects fourth quarter earnings of $4.00 to $4.20 per share on revenue of $3.25 billion to $3.45 billion. The company's previous guidance was for earnings of $3.98 to $4.18 per share on revenue of $3.20 billion to $3.40 billion and the current consensus earnings estimate is $4.00 per share on revenue of $3.31 billion for the quarter ending December 31, 2015.
Withdraws Guidance
Q 12/2015
2/29/2016
4:33:00 AM
$2.59
$2.75 bill
-18.4%
-14.2%
Guidance:
Consensus:
Valeant Pharmaceuticals Withdraws Guidance

Valeant Pharmaceuticals International, Inc. said it is withdrawing its previous guidance for fourth quarter earnings of $2.55 to $2.65 per share on revenue of $2.70 billion to $2.80 billion. The current consensus earnings estimate is $2.59 per share on revenue of $2.75 billion for the quarter ending December 31, 2015.
EPS & Revenue Below Estimates
FY 2016
3/15/2016
6:00:00 AM
$9.50 to $10.50
-
-40.4%
Guidance:
Consensus:
Valeant Lowers Guidance

Valeant Pharmaceuticals International, Inc. said it now expects first quarter earnings of $1.30 to $1.55 per share on revenue of $2.30 billion to $2.40 billion and 2016 earnings of $9.50 to $10.50 per share on revenue of $11.0 billion to $11.2 billion. The company's previous guidance was first quarter earnings of $2.35 to $2.55 per share on revenue of $2.80 to $3.10 billion and 2016 earnings of $13.25 to $13.75 per share on revenue of $12.50 billion to $12.70 billion. The current consensus earnings estimate is $2.66 per share on revenue of $2.82 billion for the quarter ending March 31, 2016 and $13.15 per share on revenue of $12.41 billion for the year ending December 31, 2016.
Reaffirms
Q 03/2016
5/9/2016
8:00:00 AM
$1.30 to $1.55
$1.39
$2.39 bill
-6.1%
-12.4%
Guidance:
Consensus:
Valeant Pharmaceuticals Reaffirms

Valeant Pharmaceuticals International, Inc. said it expects first quarter earnings of $1.30 to $1.55 per share on revenue of $2.30 billion to $2.40 billion. The current consensus earnings estimate is $1.39 per share on revenue of $2.39 billion for the quarter ending March 31, 2016.
EPS & Revenue Below Estimates
FY 2016
6/7/2016
6:00:00 AM
$6.60 to $7.00
$9.90 bil to $10.10 bil
$8.58
$10.86 bil
-14.6%
1.4%
Guidance:
Consensus:
Valeant Lowers Guidance

Valeant Pharmaceuticals International, Inc. said it now expects 2016 earnings of $6.60 to $7.00 per share on revenue of $9.90 billion to $10.10 billion. The company's previous guidance was earnings of $8.50 to $9.50 per share on revenue of $11.00 billion to $11.20 billion and the current consensus earnings estimate is $8.58 per share on revenue of $10.86 billion for the year ending December 31, 2016.
Reaffirms
FY 2016
8/9/2016
6:00:00 AM
$6.60 to $7.00
$9.90 bil to $10.10 bil
$6.81
$10.18 bil
25.4%
10.5%
Guidance:
Consensus:
Valeant Reaffirms

Valeant Pharmaceuticals International, Inc. said it continues to expect 2016 earnings of $6.60 to $7.00 per share on revenue of $9.90 billion to $10.10 billion. The current consensus earnings estimate is $6.81 per share on revenue of $10.18 billion for the year ending December 31, 2016.
EPS Below Estimates
FY 2016
11/8/2016
6:00:00 AM
$5.30 to $5.50
$9.55 bil to $9.65 bil
$6.51
$9.98 bil
-21.7%
30.2%
Guidance:
Consensus:
Valeant Pharmaceuticals Lowers Guidance

Valeant Pharmaceuticals International, Inc. said it expects 2016 earnings of $5.30 to $5.50 per share on revenue of $9.55 billion to $9.65 billion. The company's previous guidance was earnings of $6.60 to $7.00 per share on revenue of $9.90 billion to $10.10 billion and the current consensus earnings estimate is $6.51 per share on revenue of $9.98 billion for the year ending December 31, 2016.
Date
Grade
Actual
Earnings
Whisper
Consensus
Estimate
Surprise
Growth
Gap
Drift
2/27/2012
8:00:00 AM
Dec '11
Q4 '11
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A+
EPS
Rev
$0.90
$688.45 Mil
-
$0.85
-
5.9%
-
89.0%
33.8%
2.2%
10.9%
5/3/2012
8:00:00 AM
Mar '12
Q1 '12
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A-
EPS
Rev
$1.14
$856.10 Mil
-
$0.97
-
17.5%
-
112.8%
51.5%
1.5%
-7.2%
8/2/2012
7:00:00 AM
Jun '12
Q2 '12
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A+
EPS
Rev
$1.01
$820.09 Mil
-
$1.00
-
1.0%
-
38.0%
34.6%
-0.8%
8.3%
11/2/2012
6:00:00 AM
Sep '12
Q3 '12
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A-
EPS
Rev
$1.11
$856.89 Mil
-
$1.09
-
1.8%
-
73.4%
50.2%
1.8%
-6.6%
2/28/2013
6:00:00 AM
Dec '12
Q4 '12
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G B-
EPS
Rev
$1.20
$986.29 Mil
-
$1.25
-
-4.0%
-
34.3%
43.3%
-0.3%
5.0%
5/2/2013
6:00:00 AM
Mar '13
Q1 '13
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G B+
EPS
Rev
$1.30
$1.1 Bil
-
$1.28
-
1.6%
-
15.9%
24.8%
1.0%
-2.2%
8/7/2013
6:00:00 AM
Jun '13
Q2 '13
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G B
EPS
Rev
$1.26
$1.1 Bil
-
$1.28
-
-1.6%
-
28.8%
33.6%
1.0%
7.3%
10/31/2013
6:00:00 AM
Sep '13
Q3 '13
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G C
EPS
Rev
$1.41
$1.5 Bil
-
$1.40
-
0.7%
-
38.4%
79.9%
-2.3%
-3.2%
2/27/2014
6:00:00 AM
Dec '13
Q4 '13
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G C-
EPS
Rev
$2.15
$2.1 Bil
-
$2.06
-
4.4%
-
91.3%
109.2%
3.4%
-8.4%
5/8/2014
6:00:00 AM
Mar '14
Q1 '14
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G C
EPS
Rev
$1.74
$1.9 Bil
-
$1.72
-
1.2%
-
46.4%
76.6%
0.3%
-7.3%
7/31/2014
6:00:00 AM
Jun '14
Q2 '14
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G C+
EPS
Rev
$1.93
$2.0 Bil
-
$1.91
-
1.0%
-
65.0%
86.3%
-5.5%
-10.2%
10/20/2014
7:00:00 AM
Sep '14
Q3 '14
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G C-
EPS
Rev
$1.95
$2.1 Bil
-
$0.61
-
219.7%
-
37.9%
33.4%
0.8%
7.8%
2/23/2015
4:27:19 AM
Dec '14
Q4 '14
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G C-
EPS
Rev
$2.59
$2.3 Bil
-
$1.29
-
100.8%
-
20.7%
10.5%
9.7%
7.0%
4/29/2015
6:00:00 AM
Mar '15
Q1 '15
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G C
EPS
Rev
$2.34
$2.2 Bil
-
$2.34
-
-
-
34.9%
16.2%
-0.5%
5.8%
7/23/2015
6:00:00 AM
Jun '15
Q2 '15
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G C+
EPS
Rev
$2.58
$2.7 Bil
-
$2.46
-
4.9%
-
37.4%
33.9%
5.0%
1.3%
10/19/2015
6:00:00 AM
Sep '15
Q3 '15
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G B-
EPS
Rev
$2.70
$2.8 Bil
-
$2.68
-
0.7%
-
42.4%
35.5%
-4.4%
-35.2%
3/15/2016
6:00:00 AM
Dec '15
Q4 '15
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G B+
EPS
Rev
$2.51
$2.8 Bil
$2.63
$2.64
$2.8 Bil
-4.6%
1.4%
-0.4%
22.3%
-22.5%
-40.4%
6/7/2016
6:00:00 AM
Mar '16
Q1 '16
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A-
EPS
Rev
$1.27
$2.4 Bil
-
$1.42
$2.4 Bil
-10.6%
-0.4%
-44.8%
8.2%
-17.5%
1.4%
8/9/2016
6:00:00 AM
Jun '16
Q2 '16
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G A
EPS
Rev
$1.40
$2.4 Bil
-
$1.59
$2.6 Bil
-11.9%
-6.6%
-45.9%
-11.4%
7.2%
10.5%
11/8/2016
6:00:00 AM
Sep '16
Q3 '16
Earnings Whisper GradeE a rn in gs Wh is pe r® ed ar G B+
EPS
Rev
$1.55
$2.5 Bil
$1.69
$1.78
$2.5 Bil
-8.3%
-0.4%
-42.7%
-11.0%
-26.9%
30.2%
EPS
Rev
-
-
-
$1.34
$2.4 Bil
-
-
-46.6%
-14.7%
EPS
Rev
-
-
-
$1.36
$2.1 Bil
-
-
7.1%
-9.8%
2/24/2011
$40.00
$1.26
$1.18 Bil
-
-
-
2/27/2012
$50.58
$2.73
$2.46 Bil
116.7%
108.5%
26.5%
2/28/2013
$67.46
$4.40
$3.55 Bil
61.2%
44.0%
33.4%
2/27/2014
$148.00
$6.19
$5.77 Bil
40.7%
62.7%
119.4%
3/15/2016
$33.51
$8.08
$10.45 Bil
30.5%
81.1%
-77.4%
3/15/2017
$15.31
$5.48
$9.71 Bil
-32.2%
-7.1%
-54.3%
3/15/2018
$77.95
$5.63
$9.78 Bil
2.7%
0.7%
409.1%
3/15/2019
-
$6.35
-
12.8%
-
-

Price Projection

Current Value
$69
351%
Projected Price
$78
409%